Volume 85, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



We need more clinical trials in the world's poorest regions to evaluate new drugs and vaccines, and also to find better ways to manage health issues. Clinical trials are expensive, time consuming, and cumbersome. However, in wealthier regions these limiting factors are being addressed to make trials less administrative and improve the designs. A good example is adaptive trial design. This innovation is becoming accepted by the regulators and has been taken up by the pharmaceutical industry to reduce product development times and costs. If this approach makes trials easier and less expensive surely we should be implementing this approach in the field of tropical medicine and international health? As yet this has rarely been proposed and there are few examples. There is a need for raising the awareness of these design approaches because they could be used to make dramatic improvements to clinical research in developing countries.


Article metrics loading...

Loading full text...

Full text loading...



  1. Nelson NJ, , 2010. Adaptive clinical trial design: has its time come? J Natl Cancer Inst 102: 12171218.[Crossref]
  2. Pullman DW, Wang X, , 2001. Adaptive design, informed consent and the ethics of research. Control Clin Trials 22: 203210.[Crossref]
  3. Mehta C, Gao P, Bhatt DL, Harrington RA, Skerjanec S, Ware JH, , 2009. Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation 119: 597605.[Crossref]
  4. Jahn-Eimermacher A, Ingel K, , 2009. Adaptive trial design: a general methodology for censored time to event data. Contemp Clin Trials 30: 171177.[Crossref]
  5. Berry DA, , 2007. Adaptive trial design. Clin Adv Hematol Oncol 5: 522524.
  6. Brown CH, Ten Have TR, Jo B, Dagne G, Wyman PA, Muthén B, Gibbons RD, , 2009. Adaptive designs for randomized trials in public health. Annu Rev Public Health 30: 125.[Crossref]
  7. FDA, 2010. Guidance for Industry: Adaptive Design for Drugs and Biologicals.
  8. Dragalin V, , 2006. Adaptive designs: terminology and classification. Drug Information Journal 40: 425435.
  9. Fegan GW, Lang TA, , 2008. Could an open-source clinical trial data-management system be what we have all been looking for? PLoS Med 5: e6.[Crossref]
  10. Nadol P, Stinson KW, Coggin W, Naicker M, Wells CD, Miller B, Nelson LJ, , 2008. Electronic tuberculosis surveillance systems: a tool for managing today's TB programs. Int J Tuberc Lung Dis 12: 816.
  11. Abayomi A, Goodridge W, Asika O, , 2006. Wireless networks for surveillance, data capture and data management in the human immunodeficiency virus epidemic care and treatment programs. Afr J Med Med Sci 35 (Suppl): 149152.
  12. Gonzalez Moran F, Munoz Criado I, Vanaclocha H, , 2008. Real time information. A necessary tool in epidemiological surveillance. Gac Sanit 22: 162167.[Crossref]
  13. Abu-Hasaballah K, James A, Aseltine RH, Jr, 2007. Lessons and pitfalls of interactive voice response in medical research. Contemp Clin Trials 28: 593602.[Crossref]
  14. Lang T, Chilengi R, Noor RA, Ogutu B, Todd JE, Kilama WA, Targett GK, , 2008. Data safety and monitoring boards for African clinical trials. Trans R Soc Trop Med Hyg 102: 11891194.[Crossref]
  15. Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, Elbourne DR, McLeer SK, Parmar MKB, Pocock SJ, Spiegelhalter DJ, Sydes MR, Walker AE, Wallace SA, , DAMOCLES Study Group, 2005. Issues in data monitoring and interim analysis of trials. Health Technol Assess 9: 1238, iii–iv.[Crossref]
  16. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J, , 2006. Adaptive designs in clinical drug development—an Executive Summary of the PhRMA Working Group. J Biopharm Stat 16: 275283.[Crossref]
  17. Liu Q, Proschan MA, Pledger GW, , 2002. A unified theory of two-stage adaptive designs. J Am Stat Assoc 97: 10341041.[Crossref]
  18. Lang TA, White NJ, Hien TT, Farrar JJ, Day NP, Angus BJ, Denis E, Merson L, Cheah PY, Kimutai R, Marsh K, , 2010. Clinical research in resource-limited settings: enhancing research capacity and working together to make trials less complicated. PLoS Negl Trop Dis 4: e619.[Crossref]
  19. Lang TA, Kokwaro GO, , 2008. Malaria drug and vaccine trials in Africa: obstacles and opportunities. Trans R Soc Trop Med Hyg 102: 710.[Crossref]
  20. Wang M, Wu YC, Tsai GF, , 2008. A regulatory view of adaptive trial design. J Formos Med Assoc 107: 38.[Crossref]
  21. Hung HM, O'Neill RT, Wang SJ, Lawrence J, , 2006. A regulatory view on adaptive/flexible clinical trial design. Biom J 48: 565573.[Crossref]
  22. Schluger N, Karunakara U, Lienhardt C, Nyirenda T, Chaisson R, , 2007. Building clinical trials capacity for tuberculosis drugs in high-burden countries. PLoS Med 4: e302.[Crossref]
  23. Razzouk D, Sharan P, Gallo C, Gureje O, Lamberte EE, de Jesus Mari J, Mazzotti G, Patel V, Swartz L, Olifson S, Levav I, de Francisco A, Saxena S, ; WHO-Global Forum for Health Research Mental Health Research Mapping Project Group, 2010. Scarcity and inequity of mental health research resources in low-and-middle income countries: a global survey. Health Policy 94: 211220.[Crossref]
  24. Mwaba P, Bates M, Green C, Kapata N, Zumla A, , 2010. Research capacity strengthening in African countries. Lancet 375: 1874.[Crossref]
  25. Dolgin E, , 2010. African networks launch to boost clinical trial capacity. Nat Med 16: 8.[Crossref]

Data & Media loading...

  • Received : 15 Mar 2011
  • Accepted : 16 Jun 2011

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error